Latest Development Programs News

Page 3 of 45
Innovaero Technologies has reported a $5.917 million FY2026 loss as it prepares to scale OWL drone production after its ASX debut and $40 million capital raise. The annual report shows a better-funded business, but one still reliant on government contracts, certification and forecast production work.
Victor Sage
Victor Sage
28 Oct 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
Nova Minerals has secured the final approvals needed to build and operate its integrated Alaska antimony project, removing a major regulatory hurdle ahead of targeted 2027 production. The US$43.4 million Phase 1 program is funded and equipped, but the company has not yet disclosed production volumes, costs or a detailed construction schedule.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Venari Minerals has funded the next stage of its Red Mountain lithium project after raising $6.1 million, while drilling and permitting advance in Nevada. The company is also testing whether strontium and magnesium can add value beyond lithium carbonate, although commercial recovery remains unproven.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Alurion Resources has moved its Amargosa bauxite project into a field development program after completing its A$50 million IPO and ASX listing. Drilling, bulk sampling and logistics work are now feeding a direct-shipping-bauxite pre-feasibility study targeted for mid-2027.
Maxwell Dee
Maxwell Dee
27 Oct 2026
BMC Minerals has reported high-grade polymetallic drilling near its proposed Yukon mine, alongside a US$8.6 million quarterly operating cash outflow and five quarters of funding at current spending rates. The company also detailed the secured Wheaton financing arrangement that underpins part of the KZK project’s funding position.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Strata Minerals advanced technical and environmental work at its Zelica Gold Project during the September quarter, while a 42,000oz maiden resource announced after quarter end gave the project a clearer development base. The company ended the period with A$1.4 million in cash and no debt, but remains pre-production and dependent on approvals, further studies and its BML Ventures partnership.
Maxwell Dee
Maxwell Dee
23 Oct 2026
dorsaVi has commercially launched its first wearable capable of analysing movement and delivering feedback directly on-device, while its RRAM chip program moves into fabrication and testing. The progress comes alongside a post-quarter A$3.0 million capital raising, against quarter-end cash of $1.12 million and operating cash outflow of about $996,000.
Sophie Babbage
Sophie Babbage
23 Oct 2026
Innovaero has reported A$3.6 million of first-quarter revenue and A$42.9 million in cash in its first post-listing quarterly update. Its core OWL-B program remains on track for Australian Defence Force certification in March 2027, but any customer order remains conditional on that milestone.
Victor Sage
Victor Sage
23 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive